Select a Contributor Response

Conversations:

What key benefits of personalized medicine do you think the public needs to know about in order to embrace this approach to health care?

View All Conversations

 

What key benefits of personalized medicine do you think the public needs to know about in order to embrace this approach to health care?

Test Name
Test Title, Test Company

Read biography×

What key benefits of personalized medicine do you think the public needs to know about in order to embrace this approach to health care?

Amy Miller
Executive Vice President, PMC

Read biography×

Amy Miller
Executive Vice President, PMC

Follow Amy on:

For nearly a decade, Amy Miller, Ph.D., Executive Vice President for the Personalized Medicine Coalition (PMC), has worked with innovators, scientists, providers, and payers to reach consensus on policy issues impacting personalized medicine.  Before joining the PMC, Miller worked in the office of the Director of the National Institute of Mental Health where she served as a liaison among the scientific community, the legislative branch, and the consumers of mental health care and their families.  A former AAAS fellow, she also served as a domestic policy advisor to Senator Jay Rockefeller.  She began her career as a researcher at National Institute of Child Health and Human Development.  Miller received a BA from the University of New Orleans and holds a doctoral degree in Human Development from the University of Connecticut.

×

What key benefits of personalized medicine do you think the public needs to know about in order to embrace this approach to health care?

Raju Kucherlapati
Professor, Department of Genetics, Harvard Medical School

Read biography×

Raju Kucherlapati
Professor, Department of Genetics, Harvard Medical School

Follow Raju on:

Raju Kucherlapati, Ph.D., is the Paul C. Cabot Professor in the Harvard Medical School Department of Genetics. He is also a professor in the Department of Medicine at Brigham and Women’s Hospital.

Dr. Kucherlapati was the first Scientific Director of the Harvard Medical School-Partners Healthcare Center for Genetics and Genomics. His research focuses on gene mapping, gene modification, and cloning disease genes. From 1989-2001, Dr. Kucherlapati was the Lola and Saul Kramer Professor of Molecular Genetics and Chairman of the Department at the Yeshiva University Albert Einstein College of Medicine. He was previously a professor in the Department of Genetics at the University of Illinois, College of Medicine. He began his research as an assistant professor in the Department of Biochemical Sciences at Princeton University.

He has chaired numerous NIH committees and served on the National Advisory Council for Human Genome Research and the NCI Mouse Models for Human Cancer Consortium. He is also a member of the Cancer Genome Atlas project of the National Institutes of Health. He is a member of the Institute of Medicine of the National Academy of Sciences and a fellow of the American Association for the Advancement of Science.

Dr. Kucherlapati received his B.S. and M.A. in Biology from universities in India, and he received his Ph.D. from the University of Illinois at Urbana, as well as conducting post-doctoral work at Yale University.

×

What key benefits of personalized medicine do you think the public needs to know about in order to embrace this approach to health care?

Donna R. Cryer, JD
President & CEO, Global Liver Institute

Read biography×

Donna R. Cryer, JD
President & CEO, Global Liver Institute

Donna R. Cryer, JD, has channeled her personal experience as an IBD and liver transplant patient into professional advocacy as president and chief executive officer of the Global Liver Institute, the innovation and collaboration platform for the liver community.  Ms. Cryer most recently served as Chair, President & Chief Executive Officer of the American Liver Foundation, the largest and oldest national non-profit organization serving liver disease patients and their families.  She was the first patient to lead the organization in its thirty-six year history.

For eight years, Ms. Cryer has led CryerHealth, a healthcare consulting firm providing strategic counsel to top biopharmaceutical companies, patient advocacy organizations, and emerging technology firms on patient engagement in health information technology, drug discovery, and clinical decision making.  

Her e-health experience includes participating in the launch of the Office of National Coordinator for HIT (ONC) consumer engagement campaign and serving on the ONC technical expert panel on patient-generated health data, participating as a member of the White House e-health equity taskforce and the judging panel on the White House design challenge on innovating the electronic patient medical record. Her blog, DCpatient – An Impatient Patient’s Perspective from Washington, DC, and twitter feed @DCpatient are listed as top resources for  insights into emerging e-patients and patient advocates.

Ms. Cryer is a patient representative to the U.S. Food and Drug Administration, a merit reviewer for the Patient Centered Outcomes Research Institute (PCORI), and a member of Stakeholder Advisory Group to the NIH Learning Health System Research Collaboratory.  Additionally, Ms. Cryer serves on the Gastroenterology Board of the American Board of Internal Medicine, the American Society of Clinical Oncology Guidelines Committee; Hepatitis B Infection Screening in Patients Receiving Chemotherapy for Treatment of Malignant Diseases,  the Board of the Personalized Medicine Coalition, a member of the Patient and Consumer Advisory Council for the Center for Medical Technology Policy, and as at an Advisor to HarborPath, a patient assistance program for those living with HIV/AIDS and HCV.

Ms. Cryer received an undergraduate degree from Harvard/Radcliffe Colleges and received a Juris Doctorate from the Georgetown University Law Center.

She resides in Washington, DC, with her husband, Dennis R. Cryer, MD, FAHA.

×

What key benefits of personalized medicine do you think the public needs to know about in order to embrace this approach to health care?

Randy Burkholder
VP, Policy, PhRMA

Read biography×

Randy Burkholder
VP, Policy, PhRMA

Follow Randy on:

Randy Burkholder is Vice President of Policy and Research at the Pharmaceutical Research and Manufacturers of America. Mr. Burkholder leads PhRMA work on policy solutions for supporting continued biopharmaceutical innovation and high-quality, patient-centered health care, including issues involving comparative effectiveness research, health technology assessment, payment and delivery reform (accountable care organizations and bundled payment policy), appropriate use and patient adherence, and personalized medicine. Mr. Burkholder represents PhRMA at federal agencies and advisory bodies including the Medicare Evidence Development and Coverage Advisory Committee, CMS’ Technical Expert Panel on oncology, and the Federal Coordinating Council for Comparative Effectiveness Research.  He also is a former member of the Board of Directors of the Personalized Medicine Coalition and serves on the Steering Committee of the Partnership to Improve Patient Care and the advisory committee for the Turning the Tide Against Cancer initiative.

Mr. Burkholder has over 17 years experience in health care policy, advocacy and communications in the medical technology and pharmaceutical industries.

Prior to joining PhRMA, Mr. Burkholder was Associate Vice President for Public Affairs at AdvaMed, the leading association of the medical device and diagnostics industries.

×

What key benefits of personalized medicine do you think the public needs to know about in order to embrace this approach to health care?

Mark Richards
Senior Vice President, Management Supervisor, KRC Research

Read biography×

Mark Richards
Senior Vice President, Management Supervisor, KRC Research

Follow Mark on:

Mark Richards is a Senior Vice President at KRC Research. He is a leader in KRC’s healthcare, risk and crisis communications, energy, and legal services practices.

Mark is a sociologist who specializes in public opinion and communications research. For the past two decades he has led quantitative and qualitative research projects to identify insights and advise public and private clients. Mark is also an expert on risk and crisis communication, issues management, and controversial facility siting.

Before joining KRC Research, Mark was Senior Research Associate with Bisconti Research, Inc. He is a member of the American Association for Public Opinion Research (AAPOR).

Mark received his Ph.D. in Sociology and Public Policy from The Union Institute in 2001.

×
This is a test modal